This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kolibianakis, E. M. Articles by Devroey, P. Search for Related Content PubMed PubMed Citation Articles by Kolibianakis, E. M. Articles by Devroey, P.

Initiation of Gonadotropin-Releasing Hormone Antagonist on Day 1 as Compared to Day 6 of Stimulation: Effect on Hormonal Levels and Follicular Development in in Vitro Fertilization Cycles

Centre for Reproductive Medicine, Dutch-Speaking Brussels Free University, 1090 Brussels, Belgium

Address all correspondence and requests for reprints to: Efstratios M. Kolibianakis, Centre for Reproductive Medicine, Dutch-Speaking Brussels Free University, Laarbeeklaan 101, 1090 Brussels, Belgium. E-mail: stratis{at}easynet.be.

The objective of the present study was to assess the effect of altering the timing of GnRH antagonist initiation on the hormonal environment and follicular development in in vitro fertilization cycles. Sixty women undergoing in vitro fertilization participated in a prospective randomized controlled trial. Patients were stimulated with a fixed dose of 200 IU recombinant FSH, starting on d 2 of the cycle, and with GnRH-antagonist, starting either on d 1 (n = 30) or on d 6 of stimulation (n = 30). A significantly lower exposure to LH (P < 0.001) and estradiol (P < 0.001) during the follicular phase was observed in the d-1 group, compared with the d-6 group of antagonist administration. No differences in follicular development were seen between the two groups on either d 6 of stimulation or on the day of human chorionic gonadotropin administration. Similar fertilization rates, implantation rates, and ongoing pregnancy rates per transfer were, in addition, present between the two groups compared. In conclusion, administration of GnRH antagonist on d 1 (compared with d 6) of stimulation is associated with a lower exposure to LH and estradiol, which does not seem to affect follicular development.

This work was supported by grants from the Fund for Scientific Research-Flanders.

Abbreviations: AUC, Area under the curve; COC, cumulus-oocyte complex; E2, estradiol; hCG, human chorionic gonadotropin; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; P, progesterone; rec-FSH, recombinant FSH; US, ultrasound.

This article has been cited by other articles:

				J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF]

				T. G. Lainas, G. K. Petsas, I. Z. Zorzovilis, G. S. Iliadis, G. T. Lainas, H. E. Cazlaris, and E. M. Kolibianakis Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development Hum. Reprod., June 1, 2007; 22(6): 1540 - 1546. [Abstract] [Full Text] [PDF]

				E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum. Reprod. Update, November 1, 2006; 12(6): 651 - 671. [Abstract] [Full Text] [PDF]

				B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen GnRH antagonists in ovarian stimulation for IVF Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340. [Abstract] [Full Text] [PDF]

				N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF]

				T. Lainas, J. Zorzovilis, G. Petsas, G. Stavropoulou, H. Cazlaris, V. Daskalaki, G. Lainas, and E. Alexopoulou In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF Hum. Reprod., September 1, 2005; 20(9): 2426 - 2433. [Abstract] [Full Text] [PDF]

				J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy Hum. Reprod., February 1, 2005; 20(2): 359 - 367. [Abstract] [Full Text] [PDF]

				X. Luo, L. Ding, and N. Chegini Gonadotropin-releasing hormone and TGF-{beta} activate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E991 - E1001. [Abstract] [Full Text] [PDF]

				I. Cedrin-Durnerin, D. Grange-Dujardin, A. Laffy, I. Parneix, N. Massin, J. Galey, L. Theron, J.P. Wolf, C. Conord, P. Clement, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study Hum. Reprod., September 1, 2004; 19(9): 1979 - 1984. [Abstract] [Full Text] [PDF]